About T S

This author has not yet filled in any details.
So far T S has created 4 blog entries.

Genemarkers Receives Pure Michigan Business Connect Grant to Begin COVID-19 Testing

Genemarkers is honored to be one of 12 small businesses and nonprofits selected to receive the Pure Michigan Business Connect COVID-19 Emergency Access and Retooling Grants program for $104K to provide COVID-19 (SARS-CoV-2) testing in their CLIA-certified laboratory in downtown Kalamazoo, Michigan.

Genemarkers began hearing the call from medical and public health experts across the country for more COVID-19 testing earlier this winter. As experts in high complexity testing, Genemarkers’ scientists have been actively planning for the addition of this test to the Company’s existing genomic testing services.

Genemarkers has over 10 years of experience with Thermo Fisher qPCR assays and will leverage this experience to offer the FDA’s Emergency Use Authorization (EUA) TaqPath™ COVID-19 Combo Kit. The test is designed to detect the virus that causes COVID-19 in respiratory specimens for nasal or oral swabs. The Company will validate the test as a Laboratory Developed Test (LDT) so it can perform testing in a 384-well format to provide optimal testing capacity and turnaround time.  “We are grateful for the opportunity to join the fight against this disease while doing what we do best,” states Dr. Anna Langerveld, President and Chief Scientific Officer.

Genemarkers has a long history of stepping up to the plate when it comes to public health crises, most recently genetic research related to opioid addiction. “Genemarkers is proud to begin providing this crucial service to address the COVID-19 pandemic,” states Mike Getz, Chief Executive Officer.

Genemarkers Receives Pure Michigan Business Connect Grant to Begin COVID-19 Testing2020-04-21T14:15:26+00:00

Dr. Jean-Philippe Therrien joins Genemarkers as Laboratory Head and Scientific Business Development Director

Genemarkers is excited to announce that Dr. Jean-Philippe “JP” Therrien has recently joined the Company as Laboratory Head and Scientific Business Development Director for our R&D Testing Division. JP has more than 20 years of experience in skin biology, with 11 years in dermal product development for both prescription and consumer health/cosmetic products and is recognized nationally and internationally as an innovative leader in the field of dermal drug development. His extensive experience will be a great asset to the Company and our customers.

His experience in photobiology, skin aging, topical drug delivery, early safety screening (drug toxicity), drug activity assessment, reconstructed skin models, ex vivo skin culture, cell-based assay and animal model development will help bring new testing capabilities to Genemarkers.

In his previous roles, JP served as Vice President of Skin Biology for Contract Research Organizations (CROs) specialized in topical drug development and as Director of Skin Biology with the Dermatology Therapeutic Area at GlaxoSmithKline (GSK, previously Stiefel).

Dr. Jean-Philippe Therrien joins Genemarkers as Laboratory Head and Scientific Business Development Director2020-03-27T17:37:59+00:00

Kalamazoo-based Genemarkers hires CEO as all signs indicate growth

Genemarkers, a Kalamazoo-based biotech company specializing in the application of genomic science to health care, pharmaceutical research, and consumer product development has appointed J. Michael Getz as Chief Executive Officer.  Previously serving as Co-owner and Treasurer of Detroit Oxygen & Medical Equipment Company (Detroit Oxygen), Getz brings over 30 years of experience in health care administration and health care supply management to the genomic technologies and pharmacogenomic (PGX) testing provider.  In his previous role at Detroit Oxygen, Mike negotiated joint venture relationships and contracts with major Michigan-based hospitals.

“We first hired Mike as a consultant, but it was clear from the get-go that he was going to help us reach the next level.” Anna Langerveld, founder of Genemarkers.  “I am a PhD scientist and Mike has an MBA from the University of Michigan.  It just made sense. More importantly, I founded Genemarkers on the core principles of quality, integrity, and service. It was apparent that Mike and I shared these values right away.”

“PGX testing can help ensure that you’re prescribed the right medication, what’s known as personalized or precision medicine, so that there’s less risk for adverse effects” Getz explained. “Our genomic technologies are clearly aligned with the future of the marketplace. Not surprisingly, health care systems are interested in this testing as a way to improve outcomes and control costs.”

A PGX test analyzes mutations in genes associated with drug metabolism and targeting.  Health care professionals can use the test results to make informed decisions about the most safe and effective medications for an individual based on their unique genetics.  “It allows us to predict how an individual will respond to a specific drug based on the presence or absence of markers in DNA,” Dr. Langerveld continued.  “Nearly everyone has a genetic mutation affecting drug metabolism.”

“I’m excited about joining the Genemarkers team. It’s a great group that is truly dedicated to providing a service that can improve patient care,” Getz said.

Dr. Langerveld will continue as President and Chief Scientific Officer, overseeing the development of new testing services, including a new test to help address opioid addiction.

Kalamazoo-based Genemarkers hires CEO as all signs indicate growth2019-12-04T13:51:16+00:00

Cannabidiol (CBD) Gene Expression Panel Debuts at SCC Annual Meeting

Genemarkers detailed how a new gene expression panel tests the biological efficacy of CBD extracts and the cosmetic formulas containing them at the Annual Scientific Meeting & Technology Showcase.

CBD is a non-psychoactive cannabinoid extracted from the hemp plant. Its effects are mediated through the CB1 and CB2 skin receptors, whose expression initiates signaling cascades relevant to both pain and inflammation.

Our data demonstrate that the topical application of CBD regulates over 150 genes in the skin. This likely affects wound healing, pigmentation, aging, acne, and more—all important considerations for companies developing skincare products.

Recent research suggests that CBD can also influence the epidermal skin barrier, hydration, and wound healing, which positively affect skin conditions like psoriasis.

Patterns of gene expression differ based on the vehicle, extract purity, and concentration, so Genemarkers recommends additional testing of individual skincare products.

Read more about the presentation of our scientific poster on Cosmetics & Toiletries, a website for cosmetic chemists, product formulators, research scientists, and R&D managers who develop and manufacture cosmetic and personal care products.

Download the Scientific Poster for Our New CBD Gene Expression Panel

Learn about the biological efficacy of CBD extracts and its applications for product development.

Cannabidiol (CBD) Gene Expression Panel Debuts at SCC Annual Meeting2020-04-21T14:18:43+00:00